Afatinib use in recurrent epithelial ovarian carcinoma

• Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies. • Targetable mutations may lead to new therapies in gynecologic cancer treatment. • Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 inhibitors. • Afatinib shows promising respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Shepherd-Littlejohn, Amanda L., Hanft, Wyatt J., Kennedy, Vanessa A., Alvarez, Edwin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639588/
https://www.ncbi.nlm.nih.gov/pubmed/31360743
http://dx.doi.org/10.1016/j.gore.2019.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639588/
https://www.ncbi.nlm.nih.gov/pubmed/31360743
http://dx.doi.org/10.1016/j.gore.2019.07.001

Ejemplares similares